Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax Malaria: A randomized, double-blind, non-inferiority trial

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Poravuth, Yi ^a   Socheat, Duong ^a   Rueangweerayut, Ronnatrai ^b   Uthaisin, Chirapong ^c   Phyo, Aung Pyae ^d   Valecha, Neena ^e   Krishnamoorthy Rao, B H ^f   Tjitra, Emiliana ^g   Purnama, Asep ^h   Borghini Fuhrer, Isabelle ⁱ   Duparc, Stephan ⁱ   Shin, Chang Sik ^j   Fleckenstein, Lawrence ^k  

^a National Malaria Center   (Cambodia)

^b MAE SOT GENERAL HOSPITAL   (Thailand)

^c Mae Ramat Hospital   (Thailand)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^f KASTURBA MEDICAL COLLEGE   (India)

^g NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^h TC Hillers General Hospital   (Indonesia)

ⁱ Medicines for Malaria Venture   (Switzerland)

^j Shin Poong Pharmaceutical Company   (South Korea)

^k UNIVERSITY OF IOWA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIPYRETIC AGENT; ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLOROQUINE; CREATINE KINASE; HEMOGLOBIN; LIVER ENZYME; PYRONARIDINE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; NAPHTHYRIDINE DERIVATIVE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAMBODIA; CHILD; COUGHING; CREATINE KINASE BLOOD LEVEL; DEATH; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL; FATIGUE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; INCIDENCE; INDIA; INDONESIA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTICENTER STUDY; MYALGIA; NEUTROPHIL; NONHUMAN; PHASE 3 CLINICAL TRIAL; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THAILAND; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; MIDDLE AGED; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME;

ARTESUNATE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; FEVER; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; NAPHTHYRIDINES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251569264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014501     Document Type: Article

References (44)

1. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, et al. (2009) Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555-566.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79-87.
3. Guerra CA, Snow RW, Hay SI (2006) Mapping the global extent of malaria in 2005. Trends Parasitol 22: 353-358.
4. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, et al. (2009) The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 4: e774.
5. Parakh A, Agarwal N, Aggarwal A, Aneja A (2009) Plasmodium vivax malaria in children: uncommon manifestations. Ann Trop Paediatr 29: 253-256.
6. Valecha N, Pinto RG, Turner GD, Kumar A, Rodrigues S, et al. (2009) Histopathology of fatal respiratory distress caused by Plasmodium vivax malaria. Am J Trop Med Hyg 81: 758-762.
7. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5: e128.
8. Park JW, Jun G, Yeom JS (2009) Plasmodium vivax malaria: status in the Republic of Korea following reemergence. Korean J Parasitol 47 (Suppl): S39-50.
9. Sleigh AC, Liu XL, Jackson S, Li P, Shang LY (1998) Resurgence of vivax malaria in Henan Province, China. Bull World Health Organ 76: 265-270.
10. Chai JY (1999) Re-emerging Plasmodium vivax malaria in the Republic of Korea. Korean J Parasitol 37: 129-143.
11. Baird JK (2009) Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 22: 508-534.
12. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN (2010) Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10: 405-416.
13. Woitsch B, Wernsdorfer G, Congpuong K, Rojanawatsirivet C, Sirichaisinthop J, et al. (2007) Susceptibility to chloroquine, mefloquine and artemisinin of Plasmodium vivax in northwestern Thailand. Wien Klin Wochenschr 119: 76-82.
14. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, et al. (2008) Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother 52: 1040-1045.
15. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, et al. (2004) Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 35: 570-574.
16. Phan GT, de Vries PJ, Tran BQ, Le HQ, Nguyen NV, et al. (2002) Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int Health 7: 858-864.
17. World Health Organization (2010) Guidelines for the treatment of malaria (second edition). Geneva: World Health Organization. Available: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf. Accessed 2010 Nov 16.
18. World Health Organization Regional Office for the Western Pacific (2004) Interregional workshop on the control of vivax malaria in East Asia (Shanghai, China, 17-20 November 2003). Manila, Philippines: World Health Organization Regional Office for the Western Pacific. Available: http://www.wpro.who.int/internet/resources.ashx/MVP/Vivax_Mal_East+Asia.pdf. Accessed 2010 Nov 16.
19. Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, et al. (2009) High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar J 8: 41.
20. Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, et al. (2010) In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother 54: 5146-5150.
21. Fu S, Xiao SH (1991) Pyronaridine: A new antimalarial drug. Parasitol Today 7: 310-313.
22. Shao BR (1990) A review of antimalarial drug pyronaridine. Chin Med J (Engl) 103: 428-434.
23. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, et al. (2008) Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 198: 911-919.
24. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, et al. (2010) Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375: 1457-1467.
25. World Health Organization (2002) Monitoring antimalarial drug resistance: report of a WHO consultation. Geneva: World Health Organization. Available: http://rbm.who.int/cmc_upload/0/000/015/800/200239.pdf. Accessed 2010 Nov 16.
26. Valecha N, Joshi H, Eapen A, Ravinderan J, Kumar A, et al. (2006) Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern. Trans R Soc Trop Med Hyg 100: 831-837.
27. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, et al. (2007) Clinical efficacy of chloroquine versus artemetherlumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 45: 111-114.
28. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, et al. (2010) Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J 9: 52.
29. Sutanto I, Suprijanto S, Nurhayati, Manoempil P, Baird JK (2009) Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. Am J Trop Med Hyg 81: 338-342.
30. de Vries PJ, Dien TK (1996) Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 52: 818-836.
31. Batty KT, Le AT, Ilett KF, Nguyen PT, Powell SM, et al. (1998) A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Am J Trop Med Hyg 59: 823-827.
32. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, et al. (2000) Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680-1685.
33. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, et al. (2009) Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A 106: 18883-18889.
34. Suwandittakul N, Chaijaroenkul W, Harnyuttanakorn P, Mungthin M, Na Bangchang K (2009) Drug resistance and in vitro susceptibility of Plasmodium falciparum in Thailand during 1988-2003. Korean J Parasitol 47: 139-144.
35. Vathsala PG, Pramanik A, Dhanasekaran S, Devi CU, Pillai CR, et al. (2004) Widespread occurrence of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene haplotype SVMNT in P. falciparum malaria in India. Am J Trop Med Hyg 70: 256-259.
36. Syafruddin D, Asih PB, Casey GJ, Maguire J, Baird JK, et al. (2005) Molecular epidemiology of Plasmodium falciparum resistance to antimalarial drugs in Indonesia. Am J Trop Med Hyg 72: 174-181.
37. Valecha N, Joshi H, Mallick PK, Sharma SK, Kumar A, et al. (2009) Low efficacy of chloroquine: time to switchover to artemisinin-based combination therapy for falciparum malaria in India. Acta Trop 111: 21-28.
38. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, et al. (1996) Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg 54: 205-209.
39. Ringwald P, Bickii J, Basco L (1996) Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 347: 24-28.
40. Ringwald P, Bickii J, Basco LK (1998) Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 26: 946-953.
41. AlKadi HO (2007) Antimalarial drug toxicity: a review. Chemotherapy 53: 385-391.
42. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, et al. (1999) Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 60: 547-555.
43. Ribeiro IR, Olliaro P (1998) Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) 58: 50-53.
44. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, et al. (2009) Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 48: 1704-1712.